التفاصيل البيبلوغرافية
| العنوان: |
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. |
| المؤلفون: |
Bouman, Heleen J., Harmsze, Ankie M., van Werkum, Jochem W., Breet, Nicoline J., Bergmeijer, Th. O., Cate, Hugoten, Hackeng, Christian M., Deneer, Vera H. M., Berg, Jurriën M. ten |
| المصدر: |
Heart; Aug2011, Vol. 97 Issue 15, p1239-1244, 6p, 1 Diagram, 4 Charts, 1 Graph |
| مصطلحات موضوعية: |
CLOPIDOGREL, CORONARY artery surgery, SURGICAL stents, BLOOD platelet activation, PLATELET activating factor, AMLODIPINE, REGRESSION analysis |
| مستخلص: |
Background An inadequate response to clopidogrel is mainly attributable to the variable formation of its active metabolite. The CYP2C19*2 loss-of-function polymorphism leads to reduced generation of the active metabolite and is, similarly to high on-treatment platelet reactivity (HPR), associated with recurrent atherothrombotic events following coronary stent implantation. Aim To determine the relative contribution of CYP2C19*2 genotype to HPR. Methods and results CYP2C19*2 genotyping and platelet function testing using 5 and 20 mmol/l ADP-induced light transmittance aggregometry (LTA), the PlateletWorks assay and the VerifyNow P2Y12 assay, were performed in 1069 clopidogrel pretreated patients undergoing elective coronary stenting (POPular study, http://clinicalTrials.govTest/ NCT00352014). The relative contributions of CYP2C19*2 genotype and clinical variables to the interindividual variability of on-treatment platelet reactivity and the occurrence of HPR were established using multivariate regression models. CYP2C19*2 carrier status was associated with a more frequent occurrence of HPR. CYP2C19*2 genotype alone could explain 5.0%, 6.2%, 4.4% and 3.7% of the variability in 5 and 20 mmol/l ADP-induced LTA, the PlateletWorks assay and the VerifyNow P2Y12 assay, respectively, which increased to 13.0%, 15.2%, 5.6% and 20.6% when clinical variables were considered as well. Besides the CYP2C19*2 genotype, multiple clinical variables could be identified as independent predictors of HPR, including age, gender, body mass index, diabetes mellitus, clopidogrel loading dose regimen, use of amlodipine and platelet count. Conclusion The CYP2C19*2 loss-of-function polymorphism is associated with a more frequent occurrence of HPR. However, the part of the interindividual variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest. [ABSTRACT FROM AUTHOR] |
|
Copyright of Heart is the property of BMJ Publishing Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
